The flotation window stays open, for now
The first quarter of 2021 sets a new record, but the tide might be starting to turn.
Biotech venture financing starts the year with a bang
With a record $7.1bn raised in the first quarter the cash available to private drug developers shows no signs of drying up.
Venture-backed medtechs rush for the exit
A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
Despite Imfinzi, US accelerated approvals surge
More and more drugs are being approved conditionally on flimsy data, and Imfinzi is just the second to be pulled after failing a confirmatory trial.
The reckoning begins for biotech-focused Spacs
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
2020 wins top of the froths for biotech stocks
It's official: dramatic share price jumps in response to clinical data have become more common.
2020 drug approvals rise despite Covid-19
Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
Focus on Covid-19 does not distract the FDA
Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.
